Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
32.47 K
Value Traded
1.11 M
Short % Float
2.11%
Days to Cover
2.4
-10.01%Week
-27.28%1 Month
+7.3%3 Month
+13.53%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
50.46 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-11.50 M
Total Shares
4.03 M
Float Shares
2.56 M
Insiders
36.63%
Institutions
42.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ELOX Catalyst Timeline
Dated clinical, regulatory and corporate events for Eloxx Pharmaceuticals, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eloxx Pharmaceuticals, Inc. Common Stock
417Total events
6Upcoming
59Tier-1 (high impact)
2008 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedexalurenTrial
First two patients dosed in Phase 2b EXACT study of exaluren in NMAS
nonsense mutation Alport syndromesource ↗
▲IND ClearanceexalurenIND
Received FDA clearance under IND to proceed with Phase 2b trial in NMAS
nonsense mutation Alport syndromesource ↗
◆Trial InitiationexalurenTrial
Phase 2b clinical trial of exaluren in NMAS expected to initiate in Q3 2026
nonsense mutation Alport syndromesource ↗
▲Orphan Drug DesignationexalurenDesignation
European Commission granted orphan medicinal product designation for exaluren in ADPKD
ADPKDsource ↗
▼Equity OfferingCorporate
Completed underwritten public offering with gross proceeds of $66.0 million
●Management ChangeCorporate
Appointed Stephen W. Webster and Nina Kjellson to board of directors
▲Full ResultsELX-02Clinical Data
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in Phase 2 open-label trial
Alport Syndromesource ↗
◆Partnership / LicenseZKN-013Corporate
Significant progress toward completion of a strategic partnership for ZKN-013
●Oral PresentationELX-02Presentation
Clinical data from Phase 2 study of ELX-02 for Alport Syndrome presented at ASN Kidney Week 2023
Alport Syndromesource ↗
▲Full ResultsELX-02Clinical Data
Phase 2 Alport patient results to date showing proteinuria reduction
Alport syndromesource ↗
▼Equity OfferingCorporate
Raised gross proceeds of $2.0 million from sale of common stock, pre-funded warrants and warrants
◆Topline ReadoutELX-02Clinical Data
Topline data including kidney biopsy results for ELX-02 in Alport syndrome expected in first half of 2023
Alport syndromesource ↗
▲IND ClearanceZKN-013IND
FDA clearance to begin SAD clinical trial for ZKN-013 in RDEB
recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutationssource ↗
▲First Patient DosedELX-02Trial
Three patients dosed in Phase 2 study of ELX-02 for Alport syndrome
Alport syndromesource ↗
●IND SubmissionZKN-013IND
IND application filed for ZKN-013 for RDEB
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
◆Topline ReadoutELX-02Clinical Data
Topline data expected for ELX-02 in Alport syndrome
Alport syndromesource ↗
●End Of Phase 2 MeetingELX-02FDA Meeting
End of Phase 2 FDA meeting for ELX-02 in Alport Syndrome
Alport Syndromesource ↗
◆Full ResultsELX-02Clinical Data
Full results from Phase 2 trial of ELX-02 in Alport Syndrome
Alport Syndromesource ↗
●Trial InitiationELX-02Trial
Initiate pivotal trial for ELX-02 in Alport Syndrome
Alport Syndromesource ↗
◆Trial InitiationZKN-013Trial
First in Human Phase 1 study start for ZKN-013 in RDEB
recessive dystrophic epidermolysis bullosasource ↗
●IND SubmissionZKN-013IND
IND submission for ZKN-013 for RDEB
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
▲Trial InitiationELX-02Trial
Started proof-of-concept Phase 2 clinical trial with ELX-02 in Alport syndrome patients
Alport syndromesource ↗
●Poster PresentationELX-02Presentation
Poster on ELX-02 activity in COL4A5 mutations at ASN Kidney Week 2022
Alport syndromesource ↗
●IND SubmissionZKN-013IND
Submit IND for ZKN-013 for RDEB
recessive dystrophic epidermolysis bullosa (RDEB)source ↗
●Poster PresentationZKN-157Presentation
Poster on ZKN-157 for colorectal cancer at EORTC-NCI-AACR Symposium
colorectal cancersource ↗
●Poster PresentationZKN-217Presentation
Poster on ZKN-217 for small cell lung cancer at EORTC-NCI-AACR Symposium
small cell lung cancersource ↗
▼Topline ReadoutELX-02Clinical Data
Topline results from Phase 2 combination trial of ELX-02 with ivacaftor in Class 1 CF
Class 1 cystic fibrosissource ↗
●Poster PresentationPresentation
Poster on RMA library phenotypic screen at International Symposium on Medicinal Chemistry
cancersource ↗
◆Topline ReadoutELX-02Clinical Data
Topline data from CF Phase 2 expansion treatment arms evaluating combination with ivacaftor
cystic fibrosis (CF)source ↗
●IND SubmissionELX-02IND
IND submission for inhaled delivery of ELX-02
Class 1 cystic fibrosissource ↗
◆Topline ReadoutELX-02Clinical Data
Topline data from CF Phase 2 expansion treatment arms evaluating combination with ivacaftor
cystic fibrosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ELOX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | ELX-02 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ELOX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ELX-02 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | 2023-08-21 | 33% proteinuria remission rate in Phase 2; N = 16; ELX-02 0.75mg/kg per SC dailyRead More | RARE Thinking for RARE Solutions Small Molecule Gene Therapy August 2023 / 2 Forward-looking statements This presentation contains forward-looking statements, which are generally statements that are not historical facts.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aggarwal SumitDirector, Officer (President and CEO), 10% Owner | Option | 260,946 1,672,756 held | $0.15 | 02/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELOX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 0.3 % | 5.55 M | 400.00 K |
ELOX Institutional Ownership Trends
ELOX Short Interest
Shares sold short, counted twice a month.
2.11%
Short % of Float
of tradable shares sold short
53.9K
Shares Sold Short
+18.2% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
22.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELOX ranks across every disease it competes in
Competitive Position is a premium feature
See how ELOX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELOX News
-ELOX
Oct 19, 2026▼ -4.1%today
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
Eloxx Pharmaceuticals has appointed Geno Germano to its Board of Directors, effective October 19, 2026. Germano brings over 35 years of biopharmaceutical experience, including leadership roles at Pfizer and other companies. His expertise is expected to support Eloxx's development of exaluren, aimed at treating rare kidney diseases.
Read more →-ELOX
Sep 11, 2026Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
Eloxx Pharmaceuticals has initiated dosing of the first two patients in its Phase 2b EXACT study for exaluren, targeting nonsense mutation Alport syndrome. This milestone is significant for the Alport syndrome community, as there are currently no FDA-approved therapies addressing the genetic cause of the disease. Topline data from the study is anticipated by mid-2027.
Read more →-ELOX
Aug 12, 2026Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Eloxx Pharmaceuticals reported a strong second quarter in 2026, highlighted by a successful public offering that raised $66 million and an uplisting to the Nasdaq. The company plans to initiate a Phase 2b clinical trial for its lead product, exaluren, in patients with nonsense mutation Alport syndrome in Q3 2026. Additionally, exaluren received orphan designation for treating autosomal dominant polycystic kidney disease (ADPKD) from the European Commission.
Read more →-ELOX
Jun 8, 2026▲ +170.5%on this news· ran to +232% by day 3
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
Eloxx Pharmaceuticals, Inc. has announced the pricing of a public offering of 2,975,000 shares at $11.00 each, along with pre-funded warrants. The offering is expected to generate $66 million in gross proceeds and will allow the company to begin trading on the Nasdaq under the ticker ELOX on June 9, 2026. The closing is anticipated for June 10, 2026, pending customary conditions.
Read more →-ELOX
Nov 12, 2024Eloxx Pharmaceuticals Announces Key Corporate Accomplishments
Eloxx Pharmaceuticals has reported significant achievements, including the presentation of data from its proof-of-concept trial in NMAS patients at ASN Kidney Week. New analyses confirmed the production of collagen types α14 and α15 in patients treated with ELX-02. Additionally, the FDA has permitted continued dosing of subjects in the Phase 1 trial of ZKN-013.
Read more →-ELOX
Jul 11, 2024▲ +10.7%on this news
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals has announced significant updates regarding its clinical pipeline and financing. The company has dosed the first two subjects in a Phase 1 trial for ZKN-013. Additionally, positive feedback from the FDA has provided a pathway for an IND submission for a Phase 2 trial of ELX-02 in NMAS patients. Eloxx has also secured $3.2 million in financing to support its clinical programs.
Read more →-ELOX
Mar 13, 2024▲ +11.3%on this news
Almirall and Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall has entered into an exclusive agreement with Eloxx Pharmaceuticals to license ZKN-013, aimed at treating rare dermatological diseases such as RDEB and JEB caused by nonsense mutations. Eloxx will receive an upfront payment of $3 million and could earn up to $470 million in milestone payments, along with tiered royalties on global sales. This collaboration highlights the potential for innovative treatments in rare disease markets.
Read more →-ELOX
Nov 13, 2023Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update Kidney morphology improved in all three patients with protein re-expression consistent with disease regression
Eloxx Pharmaceuticals reported its financial results for Q3 2023, demonstrating improved outcomes in its Phase 2 clinical trial for ELX-02, where kidney morphology showed enhancements in all treated patients. The company's financials reflected a reduced net loss of $3.6 million, down from $7.5 million in the same quarter last year. Additionally, Eloxx is progressing towards a strategic partnership for ZKN-013 while managing challenges related to its stock delisting from Nasdaq. With cash reserves of $4.8 million, they aim to support operations into 2024.
Read more →-ELOX
Aug 21, 2023RARE Thinking for RARE Solutions Small Molecule Gene Therapy August 2023 / 2 Forward-looking statements This presentation contains forward-looking statements, which are generally statements that are not historical facts.
The article discusses the promising results of ELX-02 in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) in organoid models and clinical trials. Data shows that ELX-02 can reduce cyst burden and improve disease outcomes, with a notable proteinuria remission rate observed in patients. The ongoing research and studies indicate a forward momentum towards pivotal trials, establishing the drug's potential in addressing PKD-related complications.
Read more →-ELOX
Jul 13, 2023▼ -19.6%on this news
Baseline characteristics of patients that have completed therapy Patient Age Sex COl4 Gene Affected Nonsense Mutation RAAS Block dose Cr (mg/dL) Proteinuria (mg/g) 4401 - 01 13 Male COL4A4 c.2906C G*; p.Ser969X Enalapr
The article presents preliminary results from a Phase 2 study on Alport syndrome patients undergoing treatment with Enalapril. Notably, patient 4401 - 02 experienced a significant reduction in proteinuria, achieving partial remission after eight weeks. However, the other two patients did not exhibit marked changes in their condition, indicating variability in treatment response. The findings suggest potential benefits of the therapy, while also highlighting the need for further investigation.
Read more →-ELOX
May 15, 2023▲ +206.2%on this news
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential t
Eloxx Pharmaceuticals has reported its financial results for Q1 2023, highlighting anticipated biopsy results for the Phase 2 study of ELX-02 aimed at treating Alport syndrome. The company received FDA clearance for a new clinical trial targeting recessive Dystrophic Epidermolysis Bullosa (RDEB). Financially, Eloxx posted a reduced net loss of $6.2 million, an improvement from the previous year's loss. However, the company's cash flow situation remains critical, necessitating careful management as it prepares for potential Phase 3 trials.
Read more →-ELOX
Apr 3, 2023Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; en
Eloxx Pharmaceuticals reported its financial results for Q4 2022, indicating a net loss of $6.3 million. The company updated its business, highlighting that three patients have been dosed in a Phase 2 study of ELX-02 for Alport syndrome, with initial positive data regarding proteinuria reduction. Additionally, the Investigational New Drug application for ZKN-013 for recessive dystrophic epidermolysis bullosa was filed, aiming to expand its drug portfolio. Eloxx indicated a timeline for possible Phase 3 study activities later in 2023, contingent on successful results.
Read more →-ELOX
Dec 2, 2022▲ +7.8%on this news
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective ELOX common stock expected to begin trading on a split-adjusted basis on
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022 - December 1, 2022 - Eloxx Pharmaceuticals, Inc. (the "Company") (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic
Read more →-ELOX
Nov 10, 2022Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonse
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half
Read more →-ELOX
Sep 14, 2022Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical signi
Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class
Read more →-ELOX
Aug 15, 2022▲ +7.7%on this news· ran to +29% by day 3
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On tra
Read more →-ELOX
Jul 5, 2022▲ +7.2%on this news· ran to +18% by day 3
Eloxx Pharmaceuticals Announces Changes to Board of Directors Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, R
Eloxx Pharmaceuticals Announces Changes to Board Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seeh
Read more →-ELOX
May 10, 2022▼ -8.7%on this news· ran to -19% by day 1
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansi
Read more →-ELOX
Mar 31, 2022Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibr
Read more →-ELOX
Nov 17, 2021Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically s
tm2133239d1_ex99-1.htm Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat c
Read more →About Eloxx Pharmaceuticals, Inc. Common Stock
HeadquartersP.O. BOX 274, ARLINGTON, MA, 02476
BIOPHARMAWATCH ELITE PLUS
Trade the next ELOX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime